Literature DB >> 26476959

A case-control study: Association between serum neuregulin 4 level and non-alcoholic fatty liver disease.

Yi-Ning Dai1, Jin-Zhou Zhu1, Zhi-Yun Fang1, De-Jian Zhao2, Xing-Yong Wan1, Hua-Tuo Zhu1, Chao-Hui Yu1, You-Ming Li3.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a great health burden. Neuregulin 4 (Nrg4) is a recently identified secret factor that may be associated with NAFLD. AIM: To investigate the association between serum Nrg4 level and NAFLD by conducting a case-control study.
METHOD: A total of 174 subjects were included. 87 NAFLD subjects and 87 age- and sex-matched non-NAFLD controls were identified by hepatic ultrasound examination. Anthropometric and biochemical data were measured and recorded. Serum Nrg4 level was evaluated by using enzyme-linked immunosorbent assay. SPSS software was used for statistical analyses.
RESULTS: Compared to the controls, subjects with NAFLD presented with reduced level of serum Nrg4 (0.40 (0.27, 0.55) vs. 0.50 (0.30, 0.81)ng/mL (median (interquartile range)), P=0.029). By multivariate logistic regression analysis, reduced serum levels of Nrg4 were associated with higher NAFLD odds (OR=0.251, 95% confidence interval=0.081-0.779, P=0.017). By dividing the distribution of serum Nrg4 level into quartiles, there was borderline statistical difference of NAFLD prevalence among the four groups (P=0.058). There was no significant difference of serum Nrg4 levels in subjects according to the grades of fatty liver by ultrasound (P=0.080). No statistical difference of serum Nrg4 level was observed between obese and non-obese subjects (P=0.932).
CONCLUSION: Decreased serum Nrg4 level is prevalent in NAFLD subjects compared to non-NAFLD controls, and is an independent risk factor associated with NAFLD, indicating that Nrg4 might have a protective role in the development of NAFLD.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Neuregulin 4; Non-alcoholic fatty liver disease; Obesity

Mesh:

Substances:

Year:  2015        PMID: 26476959     DOI: 10.1016/j.metabol.2015.08.013

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  19 in total

Review 1.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

2.  Circulating neuregulin 4 concentrations in patients with newly diagnosed type 2 diabetes: a cross-sectional study.

Authors:  Lei Zhang; Yuming Fu; Nan Zhou; Xingbo Cheng; Chao Chen
Journal:  Endocrine       Date:  2017-05-18       Impact factor: 3.633

3.  NRG1-Fc improves metabolic health via dual hepatic and central action.

Authors:  Peng Zhang; Henry Kuang; Yanlin He; Sharon O Idiga; Siming Li; Zhimin Chen; Zhao Yang; Xing Cai; Kezhong Zhang; Matthew J Potthoff; Yong Xu; Jiandie D Lin
Journal:  JCI Insight       Date:  2018-03-08

4.  Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment.

Authors:  Peng Zhang; Zhimin Chen; Henry Kuang; Tongyu Liu; Jiaqiang Zhu; Linkang Zhou; Qiuyu Wang; Xuelian Xiong; Ziyi Meng; Xiaoxue Qiu; Ramiah Jacks; Lu Liu; Siming Li; Carey N Lumeng; Qing Li; Xiang Zhou; Jiandie D Lin
Journal:  Cell Metab       Date:  2022-08-15       Impact factor: 31.373

Review 5.  Brown and Beige Adipose Tissue: Therapy for Obesity and Its Comorbidities?

Authors:  Anny Mulya; John P Kirwan
Journal:  Endocrinol Metab Clin North Am       Date:  2016-09       Impact factor: 4.741

6.  Adiposity Measurements and Metabolic Syndrome Are Linked Through Circulating Neuregulin 4 and Adipsin Levels in Obese Adults.

Authors:  Dan Guo; Jianfang Liu; Peizhen Zhang; Xiaoyu Yang; Deying Liu; Jiayang Lin; Xueyun Wei; Bingyan Xu; Chensihan Huang; Xuan Zhou; Fei Teng; Hong Zhu; Huijie Zhang
Journal:  Front Physiol       Date:  2021-05-04       Impact factor: 4.566

7.  Association of circulating neuregulin 4 with metabolic syndrome in obese adults: a cross-sectional study.

Authors:  Chengfu Cai; Mingzhu Lin; Yanfang Xu; Xuejun Li; Shuyu Yang; Huijie Zhang
Journal:  BMC Med       Date:  2016-10-24       Impact factor: 8.775

8.  Circulating neuregulin 4 levels are inversely associated with subclinical cardiovascular disease in obese adults.

Authors:  Jie Jiang; Mingzhu Lin; Yanfang Xu; Jin Shao; Xuejun Li; Huijie Zhang; Shuyu Yang
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

9.  Plasma Neuregulin 4 Levels Are Associated with Metabolic Syndrome in Patients Newly Diagnosed with Type 2 Diabetes Mellitus.

Authors:  Pijun Yan; Yong Xu; Qin Wan; Jian Feng; Hua Li; Jun Yang; Haihua Zhong; Zhihong Zhang
Journal:  Dis Markers       Date:  2018-03-12       Impact factor: 3.434

10.  Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression.

Authors:  Liang Guo; Peng Zhang; Zhimin Chen; Houjun Xia; Siming Li; Yanqiao Zhang; Sune Kobberup; Weiping Zou; Jiandie D Lin
Journal:  J Clin Invest       Date:  2017-11-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.